Patient Centricity & Collaboration World Congress Europe

5th Patient Centricity & Collaboration World Congress 2024 Europe

Patient empowerment and understanding to inspire and create a meaningful impact.

00Days
00Hours
00Minutes
00Seconds

Patient meets Innovation & Collaboration

Patient empowerment and understanding to inspire and create a meaningful impact.

Introduction
Insight
Who Should Attend

Facilitate Live is very pleased to welcome you to our upcoming Patient Centricity and Collaboration World Congress 2024 Europe.
The two-day Congress aims to build meaningful collaborations within the industry, advocacy groups, clinicians, researchers, and most importantly, patients and their caregivers. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts in achieving this goal.

The congress focuses on a “Patient empowerment and understanding to inspire and create a meaningful impact. ”.

Patient-centricity is a vital aspect in the research and development of biopharmaceutical products, disease management, designing a treatment, clinical trial, or other health solutions. In order to create a patient-centric solution, one must truly embrace a collaborative endeavor with the patient and their caregivers. Establishing a patient-centric solution involves getting feedback from real patients and their loved ones, and making decisions based on their medical conditions, experiences, needs, perspectives, and priorities.

In the current climate where the patients are increasingly becoming more empowered, Lifesciences and Pharmaceutical companies should confront the status quo and welcome the opportunities to embrace a wide range of patient-centered perspectives presented by an emerging ecosystem. While the technology-driven world poses challenges, it also holds opportunities to build a positive patient experience by coordinating the health ecosystem to center on the patient. Reevaluating how it develops and delivers drugs to improve experiences and outcomes and also to continuously adapt and transform to meet the evolving needs of patients.

The industry has come a long way with utilizing a patient-centered approach. The concept has gone from a buzzword to a potential trend, to a perceivable goal. Whilst the industry has advanced in recent years, the evolving healthcare model and ecosystem brought forward by advances in technology and more involved, empowered patients, means true patient centricity is a continuing quest and a compelling commitment.

We look forward to meeting you at the Congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events / Facilitate Live

GAIN LATEST INSIGHTS ON:

What does patient centricity mean for the pharmaceutical and life science industry?
Why does the industry need to be a part of the patient-centric movement?
Patient-centric initiatives that have a tremendous impact
Successful strategies and best practices to successfully manage patient-centricity in healthcare
How to develop and execute a strategy to improve patient engagement?
Benefits of patient engagement in drug development and discovery process
Evolving challenges and key considerations inthe ethical and compliant use of relevant data
The potential value of providing access to relevant data to all stakeholders
How to maintain mutually beneficial ongoing partnerships between the patients and industry?
Overcoming myriad challenges to make the clinical trial and drug development process more patient-centred or patient-focused
Setting the pace and expectations thru collaborations
Role of researchers in bridging the communication gap between life science industry and the patient it serves
How to achieve a deeper understanding of the patient experience in the real world.
Practical ways in putting the patient at thecentre of a powerful brand

WHO SHOULD ATTEND?

This Congress is beneficial to patients, pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology, and healthcare companies.

Network with Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:

Head of Patient Engagement
Patient Services
Engagement Strategy
R&D Patient Engagement
Medical Affairs
Regulatory Affairs and Policy
Patient Support and Patient Engagement
RWE, and Data Management
Quality and Compliance
Clinical Development
Programme Management
Supply Chain Management
Patient Access
Clinical Research
Global Head, Digital Accelerator
Patient Engagement & Portfolio Strategy
Patient Support Strategy & Insights
Patient Experience

Medical Affairs, Global Patient Advocacy & Alliances
Government Policy and Advocacy
Digital Patient Experience Lead
Clinical Operations
Clinical Insights and Experience
Head of Strategy, Access Services
Vice President, Site Collaborations and Patient Centricity
Head of Neuroscience
And much more...

Key Industry Expert Speakers

Upcoming 2024 & Previous 2023 Industry Speakers

Comfirmed speakers Apply to speak

Schedule

Content Rich Program Agenda! Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Day 1 26/02/2024
Day 2 27/02/2024

Auditorium 1

07:45 am - WELCOME COFFEE & REGISTRATION

08:30 am - CHAIRPERSON’S OPENING REMARKS

Emma Sutcliffe, Global Patient Officer, Ipsen Biopharma

TRENDS & STRATEGIES IN INTEGRATING PATIENT VOICE

8:40 am - OPENING KEYNOTE PANEL: Realizing the importance of patient needs and engagement in improving patient outcomes?

The value of engaging and communicating with the patient in every part of the clinical research process
Examining the right approach for patient and industry to positively impact healthcare costs and patient outcomes through patient engagement
How can patient expertise create significant value to the industry?
What are the best practices and strategies to guarantee that patient centricity is at the forefront of pharma?

Moderator:
TBC
Panelists:

9:20 am - PLENARY KEYNOTE : Patient 3.0: milestones in engagement from patient empowerment to patient evidence

Empowerment, experience, evidence – the impact of the patient voice
Engagement delivers value as a triple win – for patients, for pharma, for society
Ensuring voice to value in the ‘Patient 3.0’ era

Emma Sutcliffe, Global Patient Officer, Ipsen Biopharma

9:50 am - Walk the Talk – Transforming from a Product Centric to Patient Centric Company....Best Practices and Learnings*

Many biotech/pharmaceutical companies are talking about ”Patient Centricity”, but how can a company actually operate in a patient-centric way to create meaningful value?
Learn best practices to transition from being product centered to patient centered
Discuss strategies to embed patient centricity throughout your organization.

Christel Paganoni-Bruijns, Global Head Community Engagement, Swedish Orphan Biovitrum AB

10:15 - MORNING NETWORKING REFRESHMENTS

10:55 am - PLENARY: Putting patients at the core of your company*

Patient Centricity requires new mindsets, relationships – and structures, company-wide.
No stage of development, from discovery through delivery, gets a pass.
No company function continues as before.
Company culture changes, too.
This isn’t easy but the results are worth the journey: to improve outcomes for patients and business performance alike.
If Patient Centricity is a fad, then it’s a failure. It should be the new way of doing business.

Bronwyn Lewis, Global Head of Patient Engagement, Boehringer Ingelheim International GmbH

11:20 am - SPONSORED SPOTLIGHT: When the tables turn on Patient Community and Pharma collaboration.

Sharing insights into a live real-world example of this type of partnership
Explaining the roles and responsibilities in achieving a positive outcome
Providing key learnings to the evolving process
Supplying the audience with guiding principles for future partnerships

11:50 am - SPONSORED SPOTLIGHT: New Advanced Technologies to Drive Speed in Clinical Trial Design

Learn about the latest technologies that can improve the efficiency and effectiveness of clinical trial design, addressing issues like increasing complexity
Discover the principles and best practices for clinical trial design that can increase the likelihood of success, through a combination of literature analysis and practical experience
Examine the challenges faced by patients during clinical trials and learn about potential solutions that can reduce the burden and increase the benefits for patients

12:20 pm - STAKEHOLDERS KEYNOTE PANEL : Targeting Patient Centricity for Maximum Impact

Understand where patient centricity can advance the interests shared by industry and the patient community
Consider how focused goals and programs can strengthen research and development, commercialization and access
Focus on opportunities to integrate patients, caregivers, consumers and advocates’ key concerns and insights into company plans and decision making
Discuss applications of this targeted approach to your patient centricity goals and programs

Moderator:

Panellist:

1:00 pm - NETWORKING LUNCH

2:00 pm - What People Want Form the Pharmaceutical and Medical Device Industry: the perspective of people living with type 1 diabetes.

The international perspective on what people with type 1 diabetes want from industry, according to international region
The Nobel Prize winning discovery of insulin in 1921 and how that legacy defines what people living with type 1 now want from industry
Type 1 diabetes patient priorities for the pharmaceutical industry and medical device industry
The rise of citizen science and how that changes the relationship that type 1 diabetes patient advocates want to be engaged with in industry research and development
A framework for patient engagement

Hilary Nathan, Policy, Communications & Community Engagement Director, JDRF

2:25 pm - Bridging the Gap Between Government, Pharmaceutical and Patients on clinical trials and research from a Patient's perspective

Education of the process of clinical trials
Listen to the Patient needs and help them to understand what the focus of the trial is.
Understanding Pharmaceutical costs of trials and research
Dealing with an illness with multiple organ involvement.
Rare Disease

2:50 pm - Patients involved in Publications: Writing the future

Why there is a need for Patient involvement in publications framework
What is the framework?
How did we co-create the framework with cross-functional team and patients – the methodology
Ongoing implementation, feedback loops early applications and expected impact

Ana Marija Gjurovic, Global Head Patient Engagement, AstraZeneca

3:15 pm - AFTERNOON NETWORKING REFRESHMENT

3:55 pm - - Path to Success: Benefits of Collaborating Fully with Patient Advocacy Groups in Trial Development

Contributions that advocacy groups can make to clinical trial development
The importance of knowing the people, their disease, and its burdens
Successful collaborations are a win for all

4:20 pm - The evolution of Patient Centric Drug Product Design within the Pharmaceutical Industry

Patient perception and usability of drug products is critical for efficacy of prescribed treatments.
Drug products should be designed to meet the specific needs of the target patient populations.
A patient centric drug product design approach is critical to support optimal therapeutic outcomes for drug products.
Roll out of digital technology will support the implementation of a patient centric mindset for drug product design.
Case-studies for drug products developed via patient centric drug product design

4:55 pm - High realistic simulation to design patient-centered clinical trial protocols

What is high realistic simulation?
How we can simulate a clinical trial protocol.
Role of patients and professionals in simulation.
Return on the investment and return on the engagement

Begoña Nafría Escalera, Coordinator of eYPAGnet, Hospital Sant Joan de Déu

5:10 pm - PANEL DISCUSSION: Path to Success: Benefits of Collaborating Fully with Patient Advocacy Groups in Trial Development

Integration of the patient perspective into the development process
Challenges and strategies for improving study protocols
Streamline your clinical trial process to drive enrollment
Contributions that advocacy groups can make to clinical trial development
The importance of knowing the people, their disease, and its burdens
Successful collaborations are a win for all

Moderator:

Panellist:

5:50 pm - CHAIRPERSON’S CLOSING REMARKS

6:00 pm - End of Day 1.

Auditorium 1

8:00 am - WELCOME COFFEE & REGISTRATION

8:30 am - CHAIRPERSON’S OPENING REMARKS

CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT

8:40 am - KEYNOTE PANEL: Increasing inclusion, diversity and equity in clinical research: Breaking down barriers to access

Why diversity and inclusion in clinical trials are crucial?
Understanding critical barriers to minority and underserved patient communities participation in clinical trials
Equity and Inclusion of Rare Disease Patients – A Must on Many Levels
What can the industry do to promote more diversity in the future?
Latest guidelines that make healthcare more inclusive

Moderator:

Panelists:

9:20 am - PLENARY SESSION: Devolvement and Implementation of Medical Evidence Patient Centricity framework

The AstraZeneca Global Patient Engagement Team has worked across the development lifecycle to embed patient-driven solutions resolving common development challenges. We will discuss how we uplifted the capabilities of our evidence teams to engage patients across the development continuum and will present examples showing what we do to impact study planning, recruitment and conduct, leading to tangible results for better patient outcomes.

Marie Eckerd, Global Patient Engagement Director R&I, BioPharmaceuticals Medical, AstraZeneca

9:45 am - JOINT PRESENTATION: The Real Cost of Patient Involvement

Limited research into the impact of patient involvement in HTA
The work is a huge undertaking for PAGS especially smaller ones
The impact of involvement on the organisation and individual
Solutions and sustainable future for PAG involvement

Lindsay Birrell, Co- CEO, Realise Advocacy, Chair of trustees, Medics 4 Rare Diseases
Josie Godfrey, Director, JG Zebra Consulting, Co-Founder and CEO, Realise Advocacy

10:10 - MORNING NETWORKING REFRESHMENTS

10:50 am - KEYNOTE PRESENTATION: Patient engagement initiatives

Patient engagement activities incorporating robust and meaningful patient engagement experiences to inform regulatory work
Considerations in patient engagement
Resources to help engage with regulatory agencies

11:15 am - CASE STUDY: Overcoming barriers and improving circumstantial awareness in clinical trials using real-world patient experience

The importance of data democratization
Common challenges in clinical data review that hinders clinical trials
Strategies in overcoming these challenges
How to seamlessly integrate data from a variety of sources?
How to improve safety review efficiencies and reduce the timeline to critical studies?

11:40 pm - SPONSORED SPOTLIGHT: Designing an end-to-end patient-centric supply chain for cell and gene therapies

Understanding complexities and addressing challenges faced by the industry in setting up end-to end supply chain for cell and gene therapies
Best practices and lessons learned that guarantees effective manufacturing and delivery of CGTs to the patients who needs them the most
Robust technologies and innovative platforms that connects therapies with patients both in clinical and commercial scale

12:10 pm - SPONSORED SPOTLIGHT: Breaking down the Conundrum to remove the logistical and financial barriers to clinical trials recruitment and retention

What are logistical and financial challenges which increasingly impact all clinical trial stakeholders
Tailored approaches to travel services for the patients
Direct-to-patient
Innovative reimbursement programmes
How to ensure patient safety and reliability

12:40 - NETWORKING LUNCH

1:40 pm - Advancing Health Equity Through People - and Patient-Centered Engagement*

This presentation will highlight how companies can advance health equity through people- and patient- centered frameworks. Learning objectives include:

Specific domains of action for addressing health equity through people and patient engagement;
Success measures of efforts to advance health equity

Anna Lawrence-Jones, Patient and Public Involvement and Engagement Lead, IGHI

2:05 pm - The art of decision making- lessons learnt and reflection.

Different interpretations of decision making across stakeholders
Value on patient outcomes and engagement (case studies)
Introduce the working model of decision making.

2:30 pm - Successful strategies and best practices to successfully manage patient-centricity and Collaboration in healthcare*

Putting the patient first achieves the best experience and outcome for that person and their family
Improve communication from staff shift-changes in a hospital to getting the patient discharged faster
Setting expectations soon
Updating goals and outcomes; timely

Amy Darlington, Executive Director, Imperial College Health Partners

2:55 pm - AFTERNOON NETWORKING REFRESHMENT

3:30 pm - PANEL DISCUSSION: The evolution of patient-centred drug development

Recognising key areas to ensure patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.
Patient’s input to improve quality, relevance, safety and efficacy of drug development
Challenges and opportunities for patient-centric product design
The role of respective stakeholders and the way they interact, from the early steps of drug development to access in real life?

4:10 pm - CLOSING PANEL DISCUSSION: Driving patient-centric healthcare: the new frontier

Understanding the drivers for innovation in pharma
Partnering with patients and placing patient well-being at the core of all initiatives
Real-world data and patient-reported outcomes presents the power and the potential to redesign healthcare
Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
Technologies that enhance the patient-centricity in pharma

4:50 pm - CHAIRPERSON’S CLOSING REMARKS

Event sponsors

Patient Centricity & Collaboration World Congress 2024 Europe

Become a sponsor/exhibitor

Newsletter Sign Up

No Spam - You will only receive relevant information on Patient Centricity & Collaboration, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.

Salvador Berrios

ERP/ CRM / Product Configurator Manager

The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations

Thomas Martin

Associate Vice President, VCGA - Quintiles

I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.